Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

doi:10.12998/wjcc.v9.i18.4491

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 9, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3155)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

267

WORD

HTML

1901

Figures (1-1)

168

Tables (1-2)

190

Sum=2617

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

196

Download

342

Sum=538

Jun 26, 2021 (publication date) through Apr 30, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Clin Cases. Jun 26, 2021; 9(18): 4491-4499
Published online Jun 26, 2021. doi: 10.12998/wjcc.v9.i18.4491

Table 2 Drug-drug interaction between antiretroviral drugs and direct-acting antiviral agents

Antiretroviral drugs	SOF/LED	SOF/VEL	SOF/VEL/VOX	EBR/GZR	GLE/PIB
NRTIs
Tenoforvir disoproxil fumarate	▲	▲	▲	-	-
NNRTIs
Efavarenz	-	X	X	X	X
Etravirenz	-	X	X	X	X
Nevirapine	-	X	X	X	X
Protease inhibitors
Atazanavir/ritonavir	-	-	X	X	X
Atazanavir/cobicistat	-	-	X	X	X
Darunavir/ritonavir	-	-	X	X	X
Darunavir/cobicistat	-	-	-	X	X
Lopinavir/ritonavir	-	-	X	X	X

▲: Should be avoided in patients with an eGFR < 60 mL/min; X: Should be avoided; EBR: Elbasvir; GLE: Glecaprevir; GZR: Grazoprevir; LDV: Ledipasvir; NNRTIs: Non-nucleoside reverse transcriptase inhibitors; NRTIs: Nucleoside reverse transcriptase inhibitors; PIB: Pibrentasvir; SOF: Sofosbuvir; VEL: Velpatasvir; VOX: Voxilaprevir.

Citation: Laiwatthanapaisan R, Sirinawasatien A. Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults. World J Clin Cases 2021; 9(18): 4491-4499
URL: https://www.wjgnet.com/2307-8960/full/v9/i18/4491.htm
DOI: https://dx.doi.org/10.12998/wjcc.v9.i18.4491